Egalet Corporation (NASDAQ:EGLT) – Investment analysts at Zacks Investment Research increased their FY2017 EPS estimates for shares of Egalet Corporation in a report released on Thursday. Zacks Investment Research analyst J. Vandermosten now forecasts that the specialty pharmaceutical company will post earnings of ($2.89) per share for the year, up from their prior estimate of ($3.01). Zacks Investment Research also issued estimates for Egalet Corporation’s Q4 2017 earnings at ($0.37) EPS and FY2019 earnings at ($0.25) EPS.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Weighs in on Egalet Corporation’s FY2017 Earnings (EGLT)” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.truebluetribune.com/2017/11/14/zacks-investment-research-weighs-in-on-egalet-corporations-fy2017-earnings-eglt.html.
Other equities analysts also recently issued reports about the company. Guggenheim set a $7.00 price target on Egalet Corporation and gave the company a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus restated a “buy” rating and set a $6.00 price target (down from $14.00) on shares of Egalet Corporation in a report on Thursday, August 10th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Egalet Corporation in a report on Monday, August 14th. Finally, Gabelli downgraded Egalet Corporation from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Egalet Corporation has a consensus rating of “Buy” and an average target price of $7.10.
Egalet Corporation (NASDAQ EGLT) opened at $0.86 on Monday. Egalet Corporation has a twelve month low of $0.85 and a twelve month high of $10.00. The company has a debt-to-equity ratio of -3.43, a quick ratio of 2.68 and a current ratio of 2.73.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EGLT. KCG Holdings Inc. increased its holdings in Egalet Corporation by 81.0% in the 1st quarter. KCG Holdings Inc. now owns 42,722 shares of the specialty pharmaceutical company’s stock worth $218,000 after buying an additional 19,116 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in Egalet Corporation by 1.1% in the 2nd quarter. Janney Montgomery Scott LLC now owns 45,963 shares of the specialty pharmaceutical company’s stock worth $109,000 after buying an additional 500 shares in the last quarter. New Jersey Better Educational Savings Trust increased its holdings in Egalet Corporation by 4.0% in the 2nd quarter. New Jersey Better Educational Savings Trust now owns 104,000 shares of the specialty pharmaceutical company’s stock worth $246,000 after buying an additional 4,000 shares in the last quarter. LMR Partners LLP bought a new stake in Egalet Corporation in the 2nd quarter worth about $179,000. Finally, Virtu KCG Holdings LLC increased its holdings in Egalet Corporation by 87.0% in the 2nd quarter. Virtu KCG Holdings LLC now owns 79,877 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 37,155 shares in the last quarter. Institutional investors own 33.39% of the company’s stock.
Egalet Corporation Company Profile
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.